
GenMark Diagnostics, Inc. GNMK
GenMark Diagnostics, Inc. Book Value 2011-2026 | GNMK
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value GenMark Diagnostics, Inc.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 196 M | 111 M | 114 M | -11.1 M | 9.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 196 M | -11.1 M | 84 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 38.96 | -0.79 % | $ 5.8 K | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 8.14 | 4.09 % | $ 584 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.14 | 3.82 % | $ 154 M | ||
|
Electromed
ELMD
|
43.2 M | $ 24.4 | 1.73 % | $ 206 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 9.7 | 3.19 % | $ 1.31 B | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.54 | 0.19 % | $ 122 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 42.97 | -0.8 % | $ 1.33 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
AxoGen
AXGN
|
129 M | $ 29.35 | -1.63 % | $ 1.35 B | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.3 | 3.94 % | $ 114 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
InMode Ltd.
INMD
|
683 M | $ 13.53 | -0.51 % | $ 874 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 105.54 | 1.2 % | $ 1.34 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 0.52 | -0.59 % | $ 53.4 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 66.57 | -2.73 % | $ 3.63 B | ||
|
Medigus Ltd.
MDGS
|
17.6 M | - | 10.28 % | $ 55.5 M | ||
|
Pulmonx Corporation
LUNG
|
85.8 M | $ 1.45 | -5.23 % | $ 56.7 M | ||
|
Cytosorbents Corporation
CTSO
|
11.1 M | $ 0.79 | -1.75 % | $ 43 M | ||
|
Medtronic PLC
MDT
|
48.3 B | $ 95.66 | -1.11 % | $ 123 B | ||
|
Align Technology
ALGN
|
3.85 B | $ 181.53 | -0.61 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
417 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.01 | 9.1 % | $ 849 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
86.7 B | $ 113.47 | -0.1 % | $ 198 B | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 72.64 | -1.64 % | $ 108 B | ||
|
Orthofix Medical
OFIX
|
450 M | $ 12.93 | -0.77 % | $ 512 M |